Medtronic Gets FDA Clearance For First MRI-Safe CRT-D Devices
Continuing its track record of introducing the first magnetic resonance imaging (MRI)-safe cardiac devices to the market, Medtronic recently gained approval from the U.S. Food and Drug Administration (FDA) for cardiac resynchronization therapy defibrillators (CRT-Ds) for heart failure patients undergoing MRI scans.
Publication date: Available online 29 May 2020Source: IDCasesAuthor(s): Anita Singh, Angel Porras, Francisco Ujueta, Saberio Lo Presti, Nicholas Camps
Publication date: June 2020Source: IJC Heart &Vasculature, Volume 28Author(s): Donato Mele, Gabriele Pestelli, Davide Dal Molin, Andrea Fiorencis, Filippo Flamigni, Giovanni Andrea Luisi, Vittorio Smarrazzo, Filippo Trevisan, Roberto Ferrari
Medtronic is recalling its HeartWare HVAD pump outflow graft and outflow graft strain relief because of the risk of breaks and tears during the pre-implant pump assembly process. FDA has identified this as a Class I recall. The Dublin-based company said it has received 92 complaints. The recalled products according to FDAâs release are: HeartWare HVAD Pump Outflow Graft and Outflow Graft Strain Relief Model Numbers:HVAD Pump Outflow Graft: 1125 HVAD Pump Implant Kit: 1103 HVAD Implant Accessories Kit: 1153 Distribution Dates: March 1, 2018 to April 1, 2020 Â Medtronic said the use of the affe...
A fair amount of effort is presently put towards the exploration of supplements derived from vitamin B3 compounds (nicotinamide, niacin, nicotinamide riboside) that act as precursors to enable the manufacture of nicotinamide adenine dinucleotide (NAD). NAD is an important component in mitochondrial activity, and levels decline with age. Some portion of the loss of mitochondrial function, implicated in the progression of many age-related conditions, is due to NAD insufficiency. There is a rich history of the use of high doses of vitamin B3 as an intervention, most of it predating modern understanding of the role of NAD in m...
(European Society of Cardiology) Save the date for HFA Discoveries, the latest scientific platform of the European Society of Cardiology (ESC). Find out what's on the horizon for prevention and treatment during this innovative online event.Worldwide, an estimated 26 million people have heart failure.1 In Europe, one-year all-cause mortality rates for acute and chronic heart failure are 23.6% and 6.4%, respectively, and heart failure hospitalisation rates are 18.7% and 9.9%, respectively.
(University of Arkansas) With funding from the National Institutes of Health, University of Arkansas researchers hope to develop the first therapeutic drug to regenerate heart tissue. The lesion-seeking drug, released through stent placement, could treat coronary blockages and prevent heart failure.
Publication date: Available online 28 May 2020Source: Preventive MedicineAuthor(s): Corinna A. Noel, Michael J. LaMonte, Mary B. Roberts, Deborah H. Pearlman, Hailey Banack, Matthew Allison, Aladdin H. Shadyab, Bernhard Haring, Deepika Laddu, Lisa Warsinger Martin, Patricia K. Nguyen, JoAnn E. Manson, Charles B. Eaton
ConclusionsEvidence of MR in retrospective claims significantly increases the clinical burden of incident HF patients. Time to death and CV hospitalizations are increased when MR is clinically significant.
This study aimed to investigate the role of testosterone in predicting major adverse cardiac events in the Chinese AR VC cohort.Methods and resultsNinety ‐nine ARVC patients (median age, 40 years; 70.7% male) and 96 healthy controls (median age, 41 years; 62.5% male) were enrolled. The circulating levels of testosterone were measured by enzyme‐linked immunosorbent assays (ELISA). The median follow‐up time of all ARVC male patients was 17 mon ths (interquartile range/IQR 9–29). Cox proportional hazards regression was used to analyse the effect of plasma testosterone and other well‐described risk...
This article is protected by copyright. All rights reserved.